Skip to main content
. 2010 Nov 2;15(11):1179–1191. doi: 10.1634/theoncologist.2009-0155

Table 1.

(Continued)

graphic file with name onc01110-0691-t02.jpg

aIFL–placebo arm already included in Hurwitz et al. (2004).

bThe bevacizumab plus erlotinib arm was not used for the meta-analysis.

Abbreviations: BV, bevacizumab; FOLFOX4, oxaliplatin + FU + LV; FU, fluorouracil; IFL, irinotecan + LV + FU; ITT, intention-to-treat analysis; LV, leucovorin; mBC, metastatic breast cancer; mCRC, metastatic colorectal cancer; mRCC, metastatic renal cell carcinoma; NR, not reported; NSCLC, non-small cell lung cancer; RCT, randomized controlled trial; XELOX, capecitabine + oxaliplatin.